Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
ISEH Annual meeting, Edinburgh
1-4 September 2022
Dr Luca Cassetta, co-founder and VP Immunology of Macomics will attend the 2022 ISEH Annual meeting.
- Speaking at Q&A session on the transition from academia to start up, 2 September 2022.
Annual Biotech in Europe Forum, Basel
21-22 September 2022
Dr Steve Myatt, CEO of Macomics, will be attending the Sachs 22nd Annual Biotech in Europe Forum, Basel, 21-22 September.
- Corporate presentation
- Participating in the Immuno-Oncology Advanced Therapeutics Panel at 3.55 pm 21 September.
Dr Steve Myatt and Dr Luca Cassetta, VP Immunology of Macomics, will be attending ImmunoUK, London 29-30 September.
- During Track 3: Targeting The Tumour Microenvironment on day two, 30 September, Dr Cassetta will be presenting on Targeting Tumour-Associated Macrophages Through Novel Antibody Therapeutics at 1.20 pm and is a panellist in the Discussion: Means Of Activating The Tumour Microenvironment at 3.40 pm.
Macrophage-directed Therapies Summit, Boston
4-6 October 2022
Dr Krzysztof Wicher, VP Head of Drug Discovery of Macomics, will attend the Macrophage-directed Therapies Summit, Boston, 4-6 October.
- Presenting in the Preclinical and Discovery session on Integrated New Macrophage Target Discovery and Validation Engine at 11 am on 5 October 2022.
24-26 October 2022
Dr Steve Myatt will be attending Bio-Europe, Leipzig, 24-26 October. Dr Steve Myatt, CEO of Macomics said:
“We continue to advance our portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic, and to invest in our target discovery platform that enables the identification and validation of novel macrophage therapeutic targets, underpinned by our deep understanding of macrophage biology.
“We are delighted that we are invited speakers at events and look forward to meeting partners, collaborators and investors face-to-face to explore opportunities to work with Macomics to maximise the opportunities for TAM-targeting therapies to address unmet needs in cancer patients.”